Indeed, CXCL12 and its receptor CXCR4 have been identified as biomarkers for ESCC and adenocarcinomas, while CXCL10, CCL4, and CCL5 have been shown to play an antitumoral role and prevent for ESCC progression [10]. Here, CXCR4 is linked to esophageal squamous cell carcinoma.